a Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences , Shandong University , Ji'nan , PR China.
Expert Opin Ther Pat. 2018 Apr;28(4):299-316. doi: 10.1080/13543776.2018.1438410. Epub 2018 Feb 13.
To deal with the rapid emergence of drug resistance challenges, together with the difficulty to eradicate the virus, off-target effects and significant cumulative drug toxicities, it is still imperative to develop next-generation anti-HIV agents with novel chemical classes or new mechanisms of action.
We primarily focused on current strategies to discover novel anti-HIV agents. Moreover, examples of anti-HIV lead compounds were mainly selected from recently patented publications (reported between 2014 and 2017). In particular, 'privileged structure'-focused substituents decorating approach, scaffold hopping, natural-product diversification and prodrug are focused on. Furthermore, exploitation of new compounds with unexplored mechanisms of action and medicinal chemistry strategies to deplete the HIV reservoir were also described. Perspectives that could inspire future anti-HIV drug discovery are delineated.
Even if a large number of patents have been disclosed recently, additional HIV inhibitors are still required, especially novel chemical skeletons displaying a unexploited mechanism of action. Current medicinal chemistry strategies are inadequate, and appropriate and new methodologies and technologies should be exploited to identify novel anti-HIV drug candidates in a time- and cost- effective manner.
为应对耐药性挑战的迅速出现,以及清除病毒的困难、非靶向效应和显著的累积药物毒性,开发具有新型化学结构或新作用机制的下一代抗 HIV 药物仍然迫在眉睫。
我们主要关注发现新型抗 HIV 药物的当前策略。此外,抗 HIV 先导化合物的例子主要选自最近的专利出版物(报告时间为 2014 年至 2017 年)。特别是,重点关注“特权结构”为导向的取代基修饰方法、骨架跃迁、天然产物多样化和前药。此外,还描述了利用作用机制和药物化学策略尚未开发的新化合物来耗尽 HIV 储存库。阐述了可以激发未来抗 HIV 药物发现的观点。
即使最近公布了大量专利,仍需要更多的 HIV 抑制剂,特别是具有未开发作用机制的新型化学骨架。当前的药物化学策略是不够的,应利用适当和新的方法学和技术,以有效和经济的方式识别新型抗 HIV 药物候选物。